<DOC>
	<DOCNO>NCT01888393</DOCNO>
	<brief_summary>This study design evaluate pharmacokinetics ( PK ) safety multiple dos lumacaftor combination ivacaftor subject moderate hepatic impairment .</brief_summary>
	<brief_title>Study Lumacaftor Combination With Ivacaftor Subjects With Moderate Hepatic Impairment Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<criteria>Group A : Subjects Moderate Hepatic Impairment Male female 18 65 year age ( inclusive ) Satisfy criterion moderate hepatic impairment define Child Pugh total score 7 9 ( Child Pugh Class B ) Screening Visit Willing able comply schedule visit , treatment , laboratory test , contraceptive guideline . Group B : Healthy subject Male female 18 65 year age ( inclusive ) Healthy subject clinically relevant abnormality identify detailed medical history , complete physical examination , include blood pressure pulse rate measurement , standard 12lead ECG , clinical laboratory test Willing able comply schedule visit , treatment , laboratory test , contraceptive guideline study procedure Group A : Subjects Moderate Hepatic Impairment History illness , opinion investigator , might confound result study pose additional risk administer study drug ( ) subject Have fluctuate rapidly deteriorate hepatic function history indicate significant variation worsen clinical and/or laboratory sign hepatic impairment within 6 month Screening Visit Other cause hepatic impairment relate parenchymal disorder and/or disease liver Severe hepatic encephalopathy Type 1 diabetes mellitus evidence poorly control type 2 diabetes Hepatocellular carcinoma , HIV , hepatitis B/C Significant renal dysfunction Solid organ bone marrow transplantation History regular alcohol consumption , drug abuse regular smoking Group B : Healthy subject History illness , opinion investigator , might confound result study pose additional risk administer study drug ( ) subject History regular alcohol consumption , drug abuse regular smoking</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>pharmacokinetics , hepatic impairment</keyword>
</DOC>